- Home
- AMRN vs CHRS Comparison
AMRN vs CHRS Comparison
Compare AMRN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMRN | CHRS |
|---|---|---|
| Founded | 1989 | 2010 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.9M | 177.7M |
| IPO Year | 1998 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AMRN | CHRS |
|---|---|---|
| Price | $13.16 | $1.14 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $5.51 |
| AVG Volume (30 Days) | 46.5K | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 55.00 | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $181,104,000.00 | N/A |
| Revenue This Year | N/A | $73.08 |
| Revenue Next Year | $1.26 | $30.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.22 | N/A |
| 52 Week Low | $12.96 | $1.09 |
| 52 Week High | $20.90 | $2.62 |
Technical Indicators
Market Signals| Indicator | AMRN | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 35.71 | 37.82 |
| Support Level | N/A | N/A |
| Resistance Level | $14.50 | $1.53 |
| Average True Range (ATR) | 0.39 | 0.09 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 11.47 | 0.00 |
Price Performance
Historical ComparisonAbout AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.